| Value | ₹61.76 Cr |
|---|
BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,374.00
- Market cap
- ₹1,14,684 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 41.0×Sector 37.9×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's allotted 5,91,270 equity shares to employees on exercise of stock options under its ADR ESOP Scheme 2007. Exercise prices ranged from Re.1 to Rs.1,060.20 per share.
Dr. Reddy's Laboratories Price Movement Clarification
Dr. Reddy's confirms FDA tentative approval for its lenacapavir HIV shot. The company states the news is not material and has no material impact.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Management Change
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Other other announcement announcements
All →Filtron Engineers Other Announcement
Filtron Engineers filed its Regulation 32 statement of deviations or variations for funds raised through a preferential issue for the quarter ended September 30, 2026. It reports no deviation, with Rs. 1,590 lakhs raised on 17/12/2025 and utilisation shown.
Bharti Hexacom Other Announcement
Bharti Hexacom informed the exchanges that its RTA, KFin Technologies, will move its corporate office effective December 1, 2026. The registered office of the RTA is unchanged.
Addictive Learning Technology Other Announcement
Addictive Learning Technology filed its half-year IPO proceeds utilisation statement under Reg 32. Reallocations moved Rs.521.32 lakh to working capital, with Rs.200 lakh unused.
JSW Dulux Other Announcement
JSW Dulux Limited filed an Audio/Video Recording intimation dated 4 November 2026 with a link to its investor page. The filing carries no transaction, financial figures, or disclosed content of the call.
CLIO Infotech Other Announcement
Clio Infotech reported no deviation in its preferential issue fund utilisation for the quarter. Rs 3,17,145 of earlier unutilised funds were used during the period.
Sattva Sukun Lifecare Other Announcement
Tavexia Lifecare Ltd board approved changing its RTA from Niche Technologies to Skyline Financial Services. Niche continues until data transition and depository confirmations are complete.